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Introduction
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) that is rather specifically expressed in the nervous system during development in mice (1) .
ALK was first identified in anaplastic large cell lymphoma as the fusion protein NPM-ALK caused by chromosomal translocation (2) . Recently, ALK was highlighted as a therapeutic target of several cancers such as non-small-cell lung cancers and colon cancers, which possess oncogenic fusion ALK proteins such as EML4-ALK (3) (4) (5) (6) . Genetic alterations of ALK have also been identified in cell lines and clinical samples of neuroblastoma, which consist of gene amplifications, activating mutations, or N-terminus truncations (7) (8) (9) (10) (11) (12) . Activated ALK proteins in neuroblastoma are distinct from other tumors as for the point that they retain the transmembrane domain.
The survival of neuroblastoma cells with activated ALK is dependent on the ALK protein in some cases, which highlights the so called oncogene addiction to activated ALK (13) .
Neuroblastoma is one of the most refractory solid tumors in children with 5-year survival rates of less than 40% following conventional treatments (14) (15) (16) . To this end, clinical trials involving neuroblastoma patients and ALK inhibitors such as crizotinib have already begun (17) . However, it was reported that neuroblastoma harboring certain types of activation mutations of ALK show greater resistance to the ALK inhibitors (18) and that there are differences in the malignancy grades among neuroblastoma cases with mutant ALK depending on the type of mutations (19, 20) .
Therefore, further investigation is necessary to elucidate what aspects of the mutant ALK protein determine the clinicopathological features of neuroblastoma.
As ALK is a receptor tyrosine kinase, it is essential to understand the signal transduction pathways which mediate the activation of this kinase. In addition to the common downstream mediators of receptor tyrosine kinases, such as Akt, Erk, and 
Purification of ALK-binding tyrosine-phosphorylated proteins
The immunoafffinity purification methods previously described (33) were modified and used for isolation of the ALK-binding tyrosine-phosphorylated proteins. The detailed protocol is described in Supplementary Materials and Methods.
Immunoblotting, immunoprecipitation, and immunofluorescence
The immunoblotting, immunoprecipitation, and immunofluorescence were done as described previously (26, 32) with modifications. The detailed protocols are described in Supplementary Materials and Methods. 
Pulse-chase analysis of ALK internalization

Biotinylation and purification of plasma membrane-localized proteins
x 10
7 cells were incubated with cold complete medium for 5 minutes at 4 °C.
The cell surface proteins were labeled with 200 g sulfo-NHSS-biotin (Thermo Scientific) for 40 minutes at 4 °C. After cell lysis, biotinylated proteins were immunoprecipitated using Ultralink Immobilized NeutrAvidin TM protein (Thermo Scientific). For internalization assay, the labeled cells were cultured in fresh complete medium at 37 °C for 60 minutes. The cell surface biotin was stripped by incubation with 180 mM sodium 2-mercaptoethane sulfonate (MesNa; Sigma). After quenching the MesNa by the addition of 180 mM iodoacetamide (Sigma) for 10 minutes, the biotinylated proteins were immunoprecipitated.
Cell migration assay
The cells (1 × 10 4 ) were seeded onto the upper part of the transwell inserts
Research. (BD Falcon) coated with fibronectin. The migrated cells on the lower surface of the filter were fixed and stained with Giemsa's stain solution. The number of migrated cells was counted using a BX51 microscope (Olympus).
Cell death assay
The cellular nuclei stained with Hoechst 33342 and PI (Thermo Scientific)
were independently counted using a fluorescence microscope (IX81-ZDC-DSU; Olympus). At least 500 cells per sample were examined and the percentage of PIpositive cells to total Hoechst-positive cells was calculated.
Anchorage-independent cell proliferation assay
Cells were cultured on MPC-coated plates (Thermo Scientific) at 1 × 10 3 cells
per six wells for 7 days and the total numbers of cells were counted.
Tumor xenograft assay
The animal experimental protocols were approved by the Committee for 
Statistical analysis
The data for all the quantitative results are expressed as mean and standard deviation from three independent experiments. Plotting of scatter graphs and testing 
Results
Identification of FLOT1 as a binding partner and kinase substrate of ALK in neuroblastoma
To identify the phosphotyrosine-containing proteins associated with anaplastic lymphoma kinase (ALK), we performed two-step affinity purification using TNB-1 neuroblastoma cells, which stably expresses the ALK protein tagged with FLAG at the C-terminus as described in Supplementary Fig. S1 . Mass spectrometry analysis identified several reported binding partners of ALK such as ShcA, ShcC and IRS1 (22, 34) along with numbers of novel candidates of ALK-binding phosphoproteins.
Association of these novel candidates with ALK was confirmed by immunoprecipitation analysis using available antibodies and further association with prognosis of neuroblastoma was checked using public database in order to estimate clinical impact. In this study, we focused on flotillin-1 (FLOT1) among these ALKbinding proteins through these screening.
The R2 database, one of the largest public databases of microarray in neuroblastoma cases (http://r2.amc.nl), indicated that high expression levels of ALK mRNA significantly correlates with poor prognosis in neuroblastoma patients ( Supplementary Fig S3) . By immunocytostaining analysis, ALK and FLOT1 were mainly co-localized within the cytoplasm, especially at the submembrane regions of the ventral membrane (Fig. 2C) .
These results suggested that FLOT1 is associated with ALK as a binding partner and kinase substrate in neuroblastoma cells.
FLOT1 regulates degradation of ALK in lysosome through endocytosis
Considering that FLOT1 is reported to be involved in endocytosis of membrane proteins, we investigated the effect of FLOT1 knockdown on the amount of membrane-localizing ALK. The amount of ALK protein at the plasma membrane was markedly increased by treatment with either of two FLOT1 siRNAs, which resulted in rather moderate increases in total ALK protein levels (Fig. 3A) . Pulsechase analysis with an ALK antibody revealed marked reduction in the amount of internalized ALK in the NB-39-nu cells treated with each FLOT1 siRNA at the time point of 30 minutes (Fig. 3B) . Biotinylation-internalization analysis confirmed that gradual increase in the total amount of internalized ALK was significantly impaired by treatment with each FLOT1 siRNA (Fig. 3C) . These results suggested that FLOT1 regulates the amount of ALK on the cell surface through endocytosis.
Membrane proteins that are internalized by endocytosis are usually degraded by the proteasome or lysosome (37) . Degradation of ALK was inhibited following treatment with the lysosomal inhibitor concanamycin, while it was not significantly affected by the proteasomal inhibitor MG132 (Fig. 3D) . Under the presence of concanamycin, accumulation of ALK at plasma membrane was observed by knockdown of FLOT1 whereas total ALK protein level was less affected (supplementary Fig. S4A ). Pulse-chase analysis visualized by immunocytostaining demonstrated the colocalization of internalized ALK with the lysosomal marker LAMP2 that was disrupted by treatment with FLOT1 siRNA (Fig. 3E) .
Colocalization of FLOT1 with internalized ALK was also observed at the early phase of endocytosis, while no obvious colocalization of ALK with the other known endosomal transporters, clathrin heavy chain and caveolin-1 (38, 39), was observed ( Supplementary Fig. S4B and C) . These results indicated that FLOT1 regulates lysosomal degradation of ALK through clathrin/caveolin-independent endocytosis. (Fig. 4A) . The increased levels of phosphorylation of these molecules were all subsequently reduced by treatment with either ALK siRNA or NVP-TAE-684, an inhibitor of ALK. We further analyzed whether the expression of FLOT1 affects the oncogenic properties of activated ALK in NB-39-nu neuroblastoma (13, 22) .
Induction of anchorage independent growth, resistance to the anticancer agent cisdiamminedichloroplatinum (cisplatin; CDDP), and cell migration were enhanced by the treatment of NB-39-nu cells with FLOT1 siRNA (Fig. 4B, Supplementary Fig.   S5A and B). Similar results were also obtained using Nagai, another neuroblastoma cell line harboring amplified wild-type ALK ( Supplementary Fig. S6A and B) . On the other hand, reduced expression and phosphorylation of ALK, and phosphorylation of AKT, ERK1/2, and STAT3 as well as induction of cell death, decreased proliferation, and acceleration of ALK internalization were observed by overexpression of FLOT1 in NB-39-nu cells (Fig. 4C, 4D, Supplementary Fig. S5C, S5D ).
To investigate whether FLOT1 has the same regulatory roles of ALK in neuroblastoma cells harboring single-copy ALK, TNB-1 cell lines stably expresses FLOT1 shRNA, TNB-FL1 and TNB-FL2 were established (Fig. 4E) . Two control lines of TNB-1 cells, TNB-Con1 and TNB-Con2 cells, were also established using the control vector. Enhanced expression of ALK and phosphorylation of AKT and ERK1/2 was observed in TNB-FL1 and TNB-FL2 cells, while no significant changes in the expression of other receptor tyrosine kinases (RTKs), such as EGFR, RET, and TrkB were observed (Fig. 4E) . In addition, increased anchorage-independent growth was detected in the TNB-FL1 and TNB-FL2 cells, which was blocked by treatment with the ALK inhibitor ( Fig. 4F and Supplementary Fig. S5E ). These results demonstrated that FLOT1 inhibits the malignant phenotype of neuroblastoma cells through endocytosis of ALK.
Activating mutations of ALK have low binding affinities to FLOT-1 and cause
ALK stabilization and malignant phenotypes in neuroblastoma cells
It is reported that some of the activating mutations of ALK such as the common F1174L mutation exhibit more malignant phenotypes and poor prognosis 
than others (19) while the mechanisms causing the differences are still not clear. We investigated differences in the binding affinities between mutant ALK proteins and FLOT1 by using TNB-1 neuroblastoma cells stably expressing wild-type (WT), F1174L (FL; mutation near the c-helix loop), K1268M (KM; mutation in the juxtamembrane domain), and R1275Q (RQ; mutation near the ATP-binding domain) mutants of ALK (8) (9) (10) (11) . FLOT1 steadily associated with the WT and RQ mutants of ALK, but not as efficiently with the FL and KM mutants (Fig. 5A) . Furthermore, knockdown of FLOT1 affected the internalization of biotinylated ALK in the WT and RQ mutants but not in the FL and KM mutants (Fig. 5B) . In addition, the phosphorylation levels of ALK, AKT, and ERK1/2 were not obviously elevated by treatment with FLOT1 siRNA in the TNB-1 cells with the FL or KM mutation (Fig. 
5B).
Anchorage-independent growth was significantly enhanced by FLOT1 siRNA in cells expressing WT or RQ mutant, whereas no obvious changes were observed in the cells expressing the FL and KM mutants, which originally showed enhanced anchorage-independent growth. Anchorage-independent growth of all the cells analyzed was reduced by treatment with the ALK inhibitor (Fig. 5C) . Similar difference in ALK mutants were also confirmed using the TNB-1 cells expressing WT ALK, the FL mutant, and the KM mutant as for resistance to CDDP and cell migration, (Supplementary Fig. S7A and B) . These results suggested that some of the activating mutations of ALK might have enhanced stability at the cell membrane by reduced affinity to FLOT1, which leads to further enhancement of the malignancy of neuroblastoma.
FLOT1 regulates tumorigenicity of neuroblastoma cells
To investigate the role of FLOT1 in the tumorigenicity of neuroblastoma, TNB-Con1/2 and TNB-FL1/2 cells were subcutaneously injected into nude mice (Fig.   6A) . Because of the low tumorigenicity of the original TNB-1 cells, tumors were not detectably formed at 6 weeks following injection of TNB-Con cells. On the other hand, tumors as large as 10-40 mm in diameter were clearly formed by the TNB-FL1
and TNB-FL2 cells in this period (Fig. 6A) . Histological study of these tumors revealed that the tumor cells had infiltrated into the muscle layers and formed large intratumoral vessels, which reflects the malignant phenotype of the tumors (Fig. 6B) .
These results indicated that FLOT1 might be a negative regulator of the malignant (Fig. 1B & 1C) , it was indicated deregulation of FLOT1 expression is involved in the progression of neuroblastoma through enhancement of ALK signaling.
Research. 
Discussion
Deregulation of the receptor tyrosine kinase ALK by amplification or activating mutation of the ALK gene has been reported in 10%-15% of human neuroblastoma cases, in which the relationship between ALK signaling and oncogenesis of neuroblastoma is indicated. While the association between ALK expression and poor prognosis of neuroblastoma is observed (Fig.1A) , it is not clear whether different modes of activation of ALK signaling are involved in the progression of the other neuroblastoma cases. In this study, we provided in vitro and in vivo evidence that activation of ALK signaling caused by impaired FLOT1-mediated endocytosis is associated with malignancy of neuroblastoma cells. This finding was supported by the observation that FLOT1 expression levels in the clinical samples is inversely correlated with prognosis of the disease in a public database (Fig.   1B) and grades of malignancy in tissue samples (Fig. 1C) . Taken together, the novel tumor-suppressing role of FLOT1 in the majority of neuroblastoma that lacks genetic alterations of ALK was implied.
There was tendency that the low expression level of FLOT1 is associated with high expression levels of ALK in the neuroblastoma tissues used for Fig.1C, while it was not statistically significant possibly due to limited numbers of tissues examined (data not shown). Therefore, we could not completely exclude the possibility that FLOT1 also degrades signaling molecules other than ALK, which are associated with malignancy of neuroblastoma, although it was confirmed that FLOT1 preferably regulates the ALK protein among several other RTKs expressed in neuroblastoma (Fig. 4E) . The information regarding the involvement of FLOT1 in cancer development is still limited (29, [40] [41] [42] . It was recently suggested that FLOT1 is associated with poor prognosis of breast cancer as a result of stabilization of ErbB2 (27) and also plays oncogenic roles in esophageal cancer and hepatocellular carcinoma (28, 40) . It is speculated that FLOT1 might regulate the organ-dependent target proteins and functions in the development of cancers and the regulation is rather selective to ALK in neuroblastoma. Considering that activated ALK found in other types of cancers lack transmembrane domain, the accumulation of membranous ALK by deficient FLOT1 might be etiological only in neuroblastoma.
It has been reported that FLOT1 physiologically acts as an endosomal transporter of membrane proteins (23) (24) (25) 
precise mechanisms of endocytosis of ALK including mode of association between FLOT1 and ALK and the role of tyrosine phosphorylation of FLOT1 in this process.
It has been reported that another RTK-binding protein Cbl is involved in the downregulation of RTKs through receptor ubiquitination followed by endocytosis.
Indeed, some mutations in the RTKs Met and EGFR decrease the affinity of RTKs with Cbl, which results in impaired endocytosis and oncogenic accumulation of RTKs in several cancers including lung cancer and glioblastoma (43) .
It was recently reported that neuroblastoma cases harboring certain activation-mutations of ALK exhibit higher refractoriness (19). For example, neuroblastoma cases harboring the F1174L mutant are also reported to have higher resistance than cases with amplified or R1275Q mutant ALK when treated with an ALK inhibitor (18). Both the F1174L and R1275Q mutations of ALK are frequently observed, while F1174L mutant is more aggressive and resistant to ALK inhibitors than R1275Q mutants even in a transgenic fly system (20). We demonstrated that the FL and KM mutants of ALK has less affinity to FLOT1 and therefore less affected by FLOT1-mediated endocytosis than the wild type ALK (Fig. 5B) . The role of oncogenic potential of ALK mutants has previously been analyzed with respect to ATP-binding potential and impaired receptor trafficking (44, 45) , while our results suggest that impaired downregulation of ALK by FLOT1 might contribute to the aggressiveness of some mutations of ALK (Supplementary Fig. S8 ). It should be emphasized that expression levels of FLOT1 might also become one of the efficient clinical markers determining prognosis and therapeutic effectiveness of ALK inhibitors in neuroblastoma cases.
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